Work

Abstract A93: Safety, efficacy and pharmacokinetics of two schedules of navitoclax (ABT-263) in combination with irinotecan: Preliminary results of an open-label phase 1 study.

Year: 2011

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-11-a93

Authors: Anthony W. Tolcher, Patricia LoRusso, Lee Rosen, Moacyr Ribeiro de Oliveira, Jeffrey F. Waring, Niki Rudersdorf, Raina Patel, Carol Ann Brasher, Todd Busman, Yue Cui, Jianning Yang, Kyle Holen

Institutions: South Texas Accelerated Research Therapeutics, The Barbara Ann Karmanos Cancer Institute, Northwest Medical Specialties, Abbott (United States)

Language: English

Topic: Cell death mechanisms and regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2314566249

Cites:

Cited by:

Related to: 10